IMV Inc. (IMV)
NASDAQ:IMV

IMV Stock Price & Analysis

359 Followers

IMV Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.24 - $1.53
Previous Close$0.25
Volume147.29K
Average Volume (3M)88.22K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$21.74M
Total Debt (Recent Filing)$28.81M
Price to Earnings (P/E)-0.5
Beta-0.10
Next EarningsMar 22, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-0.50
Shares Outstanding82,369,960
R-Squared0.02
Standard Deviation0.49
10 Day Avg. Volume81,447
30 Day Avg. Volume88,222
Price to Book (P/B)-3.77
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-0.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside5552.17% Upside
Rating ConsensusModerate Buy
Alpha0.02
Number of Analyst Covering1


Financials


IMV FAQ

What was IMV’s price range in the past 12 months?
IMV lowest stock price was $0.23 and its highest was $1.53 in the past 12 months.
    What is IMV’s market cap?
    Currently, no data Available
    When is IMV’s upcoming earnings report date?
    IMV’s upcoming earnings report date is Mar 22, 2023 which is in 102 days.
      How were IMV’s earnings last quarter?
      IMV released its earnings results on Nov 10, 2022. The company reported -$0.106 earnings per share for the quarter, beating the consensus estimate of -$0.136 by $0.03.
        Is IMV overvalued?
        According to Wall Street analysts IMV’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does IMV pay dividends?
          IMV does not currently pay dividends.
          What is IMV’s EPS estimate?
          IMV’s EPS estimate is -$0.13.
            How many shares outstanding does IMV have?
            IMV has 82,369,960 shares outstanding.
              What happened to IMV’s price movement after its last earnings report?
              IMV reported an EPS of -$0.106 in its last earnings report, beating expectations of -$0.136. Following the earnings report the stock price went down -3.125%.
                Which hedge fund is a major shareholder of IMV?
                Currently, no hedge funds are holding shares in IMV

                ---

                IMV Stock Smart Score

                N/A
                Not Ranked
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10

                Technicals

                SMA
                Negative
                20 days / 200 days
                Momentum
                -84.17%
                12-Months-Change

                Fundamentals

                Return on Equity
                -310.41%
                Trailing 12-Months
                Asset Growth
                -34.89%
                Trailing 12-Months
                This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                Learn more about TipRanks Smart Score

                Company Description

                IMV Inc.

                IMV, Inc. is a clinical-stage biopharmaceutical company pioneering a new class of immunotherapy in Oncology. Its proprietary drug delivery platform (DPX) enables the programming of immune cells in vivo. The firm's candidate, DPX-Survivac, is a T cell-activating immunotherapy combining DPX with a specific tumor target: Survivin. DPX-Survivac is in clinical evaluation as a monotherapy in advanced ovarian cancer and in combination with Merck's Keytruda across multiple cancer indications. The company was founded by Warwick Kimmins and Brian E. Lowe on March 28, 2000 and is headquartered in Dartmouth, Canada.

                ---

                Forecast EPS vs Actual EPS


                Similar Stocks
                Company
                Price & Change
                Follow
                Covalon Technologies
                Resverlogix
                Helix BioPharma
                Sirona Biochem
                Medicenna Therapeutics Corp

                Popular Stocks

                ---
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis